Jade Biosciences
JBIO
13.77
+0.36
+2.68%
Jade Biosciences
US · JBIO
#3338 by market cap
Listed 2021
13.77
+0.36
+2.68%
Live - 5344 symbols - heartbeat 168s ago
· 2026-10-08 08:46
Pre-market
13.30
-3.41%
After-hours
13.00
-5.59%
- Market cap
- 875.74M
- P/E (TTM)i
- -12.87
- P/Bi
- 1.99
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 28%
Reader sentiment
Are you bullish or bearish on JBIO?
Anonymous reader poll. Unscientific, not investment advice.
About Jade Biosciences
Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
- Founded
- 2018
- CEO
- Mr. Tom Frohlich
- Employees
- 55
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- jadebiosciences.com
Company profile
- Exchange
- US
- Symbol
- JBIO
- Market-cap rank
- #3338
- Listing date
- 2021-06-30
- Market cap
- 875.74M
- Float cap
- 715.67M
- Shares out
- 63.60M
- Float shares
- 51.97M
Sectors & themes
Quote time 2026-10-08 08:46:53 · For reference only, not investment advice and not tailored to your situation.